Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vinblastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinblastine SCHEMBL28131624 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL2923482 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29879166 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL6340124 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL3550 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29594152 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29554704 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL5535862 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL3549 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL5306718 | 0.99 | MAPT (0.99) | MAPTMEN1KMT2ALMNATUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 768 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009778-A1 | KRAS ANTAGONISTS | TRUETIVA INC (US) | 2025-01-09 | — | — | US | claimed |
| EP-3243835-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-04-10 | — | — | EP | claimed |
| US-11952353-B2 | STAT3 transcription factor inhibitors and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2024-04-09 | — | — | US | claimed |
| EP-3337816-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-02-14 | — | — | EP | claimed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| US-20230173295-A1 | Systems, Devices, and Methods for Gamma Entrainment using Sensory Stimuli to Alleviate Cognitive Deficits and/or Neuroinflammation Induced by Chemotherapy Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-08 | — | — | US | claimed |
| WO-2023055904-A1 | KRAS ANTAGONISTS | TRUETIVA, Inc. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| US-20220117990-A1 | KRAS ANTAGONISTS | TRUETIVA, Inc. (US) | 2022-04-21 | — | — | US | claimed |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| EP-3325504-B1 | METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| CN-122079960-A | Alkynyl quinazoline compounds | — | 2026-05-26 | — | — | CN | disclosed |
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | TERRESTRIAL BIO, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | MARENGO THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20220054565-A1 | Platform Oncolytic Vector for Systemic Delivery | KALIVIR IMMUNOTHERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11253559-B2 | Oncolytic viruses targeting STAT3 | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220049228-A1 | Modified Extracellular Enveloped Virus | KALIVIR IMMUNOTHERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| WO-2022026915-A2 | ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME | ANGIEX, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-11230568-B2 | Melanocortin 1 receptor ligands and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | GLP1R, NPY1R, NPY4R | TUBB4A 2787/4885TUBB 2137/4885TUBA3C 1779/4885 |
| US-11230568-B2 | Melanocortin 1 receptor ligands and methods of use | MC1R, MC3R, MC5R | TUBB4A 4136/4885TUBB 3909/4885TUBA3C 3588/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | TUBB4A 2136/4885TUBB 2256/4885TUBA3C 3020/4885 |
| US-20250009778-A1 | KRAS ANTAGONISTS | KRAS, NRAS, HRAS | TUBB4A 4521/4885TUBB 4346/4885TUBA3C 4764/4885 |
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | CD2, CD4, CD47 | TUBB4A 1411/4885TUBB 1439/4885TUBA3C 2761/4885 |
| US-20220117990-A1 | KRAS ANTAGONISTS | KRAS, NRAS, HRAS | TUBB4A 4521/4885TUBB 4346/4885TUBA3C 4764/4885 |
| US-11952353-B2 | STAT3 transcription factor inhibitors and methods of using the same | STAT3, STAT1, STAT5A | TUBB4A 3440/4885TUBB 3441/4885TUBA3C 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.